Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965391 | 0.95 | LTA4H (0.64) | LTA4HSLC6A2HRH2HTR2AHTR2B | |
| SCHEMBL7335832 | 0.90 | LTA4H (0.74) | LTA4H | |
| Hydrochloric Acid SCHEMBL7334091 | 0.88 | LTA4H (0.72) | LTA4H | |
| SCHEMBL6611442 | 0.87 | LTA4H (0.62) | LTA4H | |
| SCHEMBL8476007 | 0.85 | LTA4H (0.55) | LTA4H | |
| SCHEMBL8590818 | 0.84 | LTA4H (0.47) | LTA4HHRH2 | |
| SCHEMBL7326422 | 0.84 | LTA4H (0.76) | LTA4H | |
| SCHEMBL13809106 | 0.84 | LTA4H (0.76) | LTA4H | |
| SCHEMBL7327575 | 0.84 | LTA4H (0.60) | LTA4HHTR2B | |
| SCHEMBL11447699 | 0.84 | LTA4H (0.61) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2004-09-30 | — | — | US | disclosed |
| EP-1435955-A2 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SmithKline Beecham P.L.C. (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2002089800-A2 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
| US-4225608-A | ANTIDEPRESSANTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1980-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | LTA4H 1671/4885SLC6A2 196/4885HRH2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.